Gland Pharma Limited announced strong financial results for the quarter ending March 31, 2026. The company achieved a 22% year-on-year revenue growth and a significant 97% increase in adjusted Profit After Tax (PAT). Driven by robust CDMO segment performance and new product launches in the U.S., the Board has recommended a final dividend of ₹20 per share, reflecting confidence in the company’s sustained momentum and long-term complex product pipeline.
Quarterly Financial Performance
For the fourth quarter of FY26, Gland Pharma reported revenue from operations of ₹17,428 million, marking a 22% increase compared to the same period last year. The company’s adjusted PAT surged to ₹3,667 million, a 97% jump year-on-year, while the adjusted EBITDA reached ₹5,244 million, representing a 51% growth. These figures highlight the successful execution of cost-efficiency initiatives and robust demand across its global markets.
CDMO and Business Segment Highlights
The CDMO segment remained a primary growth driver, contributing 46% to the company’s total revenue in Q4 FY26 and experiencing a 36% year-on-year growth. This momentum is supported by new CDMO contracts, including a complex Nano Drug Delivery System based injectable project. The base business also performed steadily, with 22% revenue growth recorded for the quarter.
Strategic R&D and Market Expansion
Innovation continues to be at the core of operations, with ₹506 million invested in R&D during the quarter. Significant milestones include the launch of five molecules in the U.S., such as Dalbavancin and Brimonidine. The company’s U.S. presence was further bolstered by eight new ANDA filings and 11 approvals in Q4. Additionally, the company has ramped up its Ready-to-Use (RTU) infusion bag portfolio, addressing a market opportunity of approximately $634 million in the U.S.
Global Facility Updates
Operations at Cenexi saw positive progress, with revenue reaching €45 million for the quarter. Strategic facility enhancements, such as the new high-capacity ampoule filling line at the Fontenay facility expected by August 2026, are set to solidify Gland Pharma’s manufacturing footprint in Europe. Meanwhile, the Hérouville and Braine-l’Alleud sites continue to maintain momentum through new product launches and hormonal PFS contracts.
Source: BSE
